New Jersey, USA (CU)_ NetScientific PLC (AIM:NSCI) announced the quarterly results of portfolio firm PDS Biotechnology Corp., stating that the company has made sustained progress in its clinical trials program and is appreciated for reinforcing its staff. According to PDS Biotech, it has maintained the momentum established by interim clinical results in the second- and third-line therapy of HPV16-positive anal, cervical, head and neck, vaginal, and vulvar malignancies.
The VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in patients with recurrent and/or metastatic head and neck cancer related to human papillomavirus (HPV)16 has reached…
